|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑 1 _( P& R" w/ |4 [( a3 h' J
4 m9 E; J' p# U3 Z$ Y( x8 F目录
/ k' Q7 {! ?% h1 M4 m5 M+ J免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 42 w3 C9 {) e3 s
抗癌领域新突破 .................................................................................................................. 4
$ A5 D$ M6 t4 n9 [- @8 a) u600 亿美元市场空间 ............................................................................................................ 4
) _7 o0 D# f( B# _免疫检查点的突破——PD-1 ....................................................................................................... 5
4 c( f( b- X0 g" |# Q! LPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5
2 `9 p; ?* W6 }4 U) R7 {! t7 ?+ kPD-1 重磅产品频出 ............................................................................................................. 59 M/ P- L$ v, ^
在研PD-1 单抗全面开花 ....................................................................................................... 6
/ v/ N0 H z+ e8 t7 @0 TPD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 77 a% j; G7 R. n \( \7 v
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
2 O, o( c' W1 s3 B# ^PD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 93 Y; z. ]( ] x, g( [0 L
PD-1 市场前景广阔 ........................................................................................................... 102 x4 |2 w* n1 a8 ?% P
免疫治疗热门靶点——PD-L1 ................................................................................................... 19 o M6 H- Y( Y3 N! }$ l
PD-L1 单抗免疫疗法原理 .................................................................................................... 19
& R# | J6 ]% w1 N; `1 kPD-L1 单抗在研情况 .......................................................................................................... 19
9 v3 R7 p& f+ t, IPD-L1 联用——多靶点治疗新选择 ......................................................................................... 19& B$ L6 U9 H: v J0 g; b
PD-L1 未来市场 ............................................................................................................... 20$ f# q- d' l& R
免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
% Y/ F; Z! \5 l" hCTLA-4 单抗免疫疗法原理 ................................................................................................... 21* j- X) g+ Z! s$ n% y
CTLA-4 单抗已上市产品 ..................................................................................................... 21! R8 T+ L( T% ~$ U2 W8 O
CTLA-4 在研产品.............................................................................................................. 22( @# [& s! a) Z! g" V# N" z
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23
( L( W5 ]6 Z2 \1 P" Y& `/ O5 P5 j相关公司简介 ........................................................................................................................ 245 ?) c9 _# x. X
君实生物 ........................................................................................................................ 24& u/ l( o0 ~# v) ^# a+ u* j
恒瑞医药（确信买入评级） .................................................................................................. 25
1 H" z4 A! e# h/ q& W6 T( b百时美施贵宝（BMS） ....................................................................................................... 26$ I" e- u0 i! Q( ?- [; g
默克（Merck） ................................................................................................................ 27
4 H6 l* ?! G& y. h; w; ~* Q( F+ c' z; c8 z! |: p2 }6 y1 }" C
2 a6 |# L& C) T' ^' `, P2 T
[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
